Click on a filter below to refine your search. Remove a filter to broaden your search.
Risks for new-onset psychiatric diagnoses and anxiety disorders, but not mood disorders, increased in the early postacute phase.
The FDA received licensing applications sooner and had shorter review times compared with the European Medicines Agency.
However, for all ages, vaccine effectiveness against severe COVID-19 was high overall, at 90% five months or longer after two doses.
Medicare spending was higher for adults with a formal clinical diagnosis of dementia versus a positive screening for cognitive impairment.
The authors say that the review findings are limited by heterogenous definitions of long COVID in published studies.
Those who walked for exercise had a reduced likelihood of new frequent knee pain and medial joint space narrowing.
Compared with placebo, normalization of C-reactive protein and oxygen saturation was faster, with improvements seen on day 3 of treatment.
No deaths have been reported in either the U.S. or other countries affected by monkeypox outbreaks.
SARS-CoV-2 vaccination appears to have no positive or negative impact on cognitive function or fatigue.
An increase in registered nurse hours per patient day was associated with a 3% decrease in 60-day mortality.